Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial

Hdl Handle:
http://hdl.handle.net/10144/619029
Title:
Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial
Authors:
Diro, E; Ritmeijer, K; Boelaert, M; Alves, F; Mohammed, R; Abongomera, C; Ravinetto, R; De Crop, M; Fikre, H; Adera, C; van Loen, H; Tsoumanis, A; Adriaensen, W; Hailu, A; van Griensven, J
Journal:
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
Abstract:
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation.
Publisher:
Oxford University Press
Issue Date:
13-Sep-2017
URI:
http://hdl.handle.net/10144/619029
DOI:
10.1093/cid/cix807
PubMed ID:
29020217
Submitted date:
2017-10-18
Language:
en
ISSN:
1537-6591
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorDiro, Een
dc.contributor.authorRitmeijer, Ken
dc.contributor.authorBoelaert, Men
dc.contributor.authorAlves, Fen
dc.contributor.authorMohammed, Ren
dc.contributor.authorAbongomera, Cen
dc.contributor.authorRavinetto, Ren
dc.contributor.authorDe Crop, Men
dc.contributor.authorFikre, Hen
dc.contributor.authorAdera, Cen
dc.contributor.authorvan Loen, Hen
dc.contributor.authorTsoumanis, Aen
dc.contributor.authorAdriaensen, Wen
dc.contributor.authorHailu, Aen
dc.contributor.authorvan Griensven, Jen
dc.date.accessioned2017-10-24T14:00:30Z-
dc.date.available2017-10-24T14:00:30Z-
dc.date.issued2017-09-13-
dc.date.submitted2017-10-18-
dc.identifier.citationLong-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial. 2017 Clin. Infect. Dis.en
dc.identifier.issn1537-6591-
dc.identifier.pmid29020217-
dc.identifier.doi10.1093/cid/cix807-
dc.identifier.urihttp://hdl.handle.net/10144/619029-
dc.description.abstractWe have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsArchived with thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen
dc.titleLong-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trialen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.